Alternative regimens including the use of multimodal analgesia have become a standard practice in acute pain management. Exparel, a long-lasting liposomal bupivacaine local anesthetic agent, has many significant benefits in the management of postoperative pain. Read more.
There has been increased interest in the use of low dose ketamine (LDK) as an alternative analgesic for the management of acute pain in the emergency department (ED). The objective of this systematic review was to compare the analgesic effectiveness and safety profile of LDK and morphine for acute pain management in the ED. Read more.
Few studies have examined primary care management for acute sciatica, including referral to physical therapy. To evaluate whether early referral to physical therapy reduced disability more than usual care (UC) alone for patients with acute sciatica. Read more.
The Evidence-based Practice Center (EPC) Program at the Agency for Healthcare Research and Quality (AHRQ) has posted the draft report for the systematic review on Treatments for Acute Pain: A Systematic Review. It is available for review and feedback until September 28, 2020. Read more.
The American College of Physicians (ACP) and American Academy of Family Physicians (AAFP) developed this guideline to provide clinical recommendations on nonpharmacologic and pharmacologic management of acute pain from non–low back, musculoskeletal injuries in adults in the outpatient setting. The guidance is based on current best available evidence about benefits and harms, taken in the context of costs and patient values and preferences. This guideline does not address noninvasive treatment of low back pain, which is covered by a separate ACP guideline that has also been endorsed by AAFP. Read the details.
The U.S. Food and Drug Administration approved Olinvyk (oliceridine), an opioid agonist for the management of moderate to severe acute pain in adults, where the pain is severe enough to require an intravenous opioid and for whom alternative treatments are inadequate. Full story.
AAPM members Beth Darnall, PhD, and Mark Wallace, MD, were appointed to the Centers for Disease Control Opioid Workgroup by the Board of Scientific Counselors of the Centers for Disease Control and Prevention’s National Center for Injury Prevention and Control (BSC/NCIPC). The Opioid Workgroup (roster), is responsible for reviewing the quality of evidence reviews and guidelines, and will make recommendations regarding revisions to existing CDC opioid prescribing guideline and the creation of new prescribing guidelines for acute and chronic pain.